[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-aggregation-inhibitors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-aggregation-inhibitors":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,85,143,173,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100423656","phase-4-antiplatelet-therapy-strategy-following-left-atrial-appendage-closure-100423656",false,"NCT04796714","AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE","APPENDAGE","Inclusion Criteria:\n\n* Male or female patients with LAAC indication according to \"Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé\" (CNEDiMTS) (National Commission for the Evaluation of Medical Devices and Health Technologies) guidelines\n* Age ≥ 18 years\n* Written informed consent provided by the patient\n* Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation\n* Registration under social security system\n\nExclusion Criteria:\n\n* Minors\n* Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation\n* LAAC contraindication : left appendage thrombus\n* Major disease resulting in a life expectancy of \\\u003C 1 year\n* Severe and inherited bleeding disorder\n* Known hypersensitivity to aspirin and\u002For clopidogrel:\n\n  * Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (cross-reaction).\n  * Asthma or a history of asthma with or without nasal polyps induced by salicylates or substances of close activity, including nonsteroidal anti-inflammatory drugs.\n  * Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.\n  * Any constitutional or acquired haemorrhagic disease.\n  * Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting).\n  * Severe liver failure.\n  * Severe kidney failure (Creatinine light \\\u003C 30ml\u002Fmin).\n  * Uncontrolled severe heart failure\n* Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intracranial metal clip, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator.\n* Guardianship\n* Curatorship\n* Pregnancy or child-bearing potential female\n* Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estrogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes))\n* Iode contraindication\n* Patient already participating in another category 1 interventional research\n* Patient in a period of exclusion relative to another research protocol.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF). The primary objective of the study is to evaluate the efficacy of Aspirin versus Aspirin + Clopidogrel after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular magnetic resonance imaging (MRI) studies.",[26,27,28,29,30],"Atrial Fibrillation","Atrial Appendage","Anticoagulants","Stroke","Platelet Aggregation Inhibitors",[32,33,34,35,36],"left atrial appendage","percutaneous closure","stroke","antiplatelet therapy","atrial fibrillation","RECRUITING","2026-06-08",{"date":40,"type":41},"2026-06-10","ACTUAL",{"date":43,"type":41},"2022-10-03",{"date":45,"type":20},"2027-05-03",{"name":47,"class":48},"University Hospital, Bordeaux","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":49},"100638631","personalizing-thromboprophylaxis-for-patients-with-peripheral-artery-disease-100638631","NCT07613840","Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease","Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease","Inclusion Criteria:\n\n* Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and\u002For closed revascularization.\n* Patients at the age of 18 or older\n\nExclusion Criteria:\n\n* Patients who are younger than 18 years old\n* Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)\n* Prisoners, defined as those who have been directly admitted from a correctional facility.\n* No atherosclerosis\n* Subject has active stomach ulcers\n* Subject has severe hepatic impairment\n* Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \\>1 year, the study team will consult with the",{"count":58,"type":20},484,[60],"NA","The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.\n\nThe main questions it aims to answer are:\n\n* Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure?\n* Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?\n\nResearchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.\n\nParticipants will:\n\n* Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure\n* Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure\n* Have medications adjusted based on blood test results if assigned to the TARGET group",[63,64,65,66,30,67,68],"Peripheral Arterial Disease (PAD)","Amputation","Thrombosis","Thrombosis (Stent Thrombosis)","Thromboelastography (TEG)","PRU(Platelet Reactivity Unit)",[70,71,72,73,74,75],"Peripheral Artery Disease Thromboprophylaxis","Personalizing Blood Thinners","Clopidogrel Resistance","Thromboelastography with Platelet Mapping (TEG-PM)","Graft\u002F Stent Thrombosis","Platelet Inhibition","2026-05-21",{"date":78,"type":41},"2026-05-29",{"date":80,"type":41},"2025-04-29",{"date":82,"type":20},"2027-06-30",{"name":84,"class":48},"Massachusetts General Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":122,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":94,"type":20},576,[60],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,30,120,121],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Myocardial Ischemia","Atherosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Coronary Artery Disease","Acute Coronary Syndrome","Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Aspirin","Clopidogrel",[123,124,125,126,127,128,129,130,131,132],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":135,"type":41},"2026-01-22",{"date":137,"type":41},"2026-01-10",{"date":139,"type":20},"2028-02-20",{"name":141,"class":48},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",1,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":142},"100493231","phase-1-assessing-pharmacokinetics-and-pharmacodynamics-of-daily-enteric-coated-aspirin-in-patients-with-stable-diabetes-ii-100493231","NCT05702463","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II","APPEASEDII","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Participant must be naïve to ASA, defined as absence of chronic treatment with ASA within the previous 3 months, and of any ASA use within the previous 2 weeks;\n3. Type 2 diabetes, based on at least one of the following criteria: (5)\n\n   * Chronic treatment with oral antihyperglycemic agents or insulin therapy;\n   * Fasting Plasma Glucose (FPG) ≥ 126 mg\u002FdL (7.0 mmol\u002FL) (fasting is defined as no caloric intake for at least 8h);\n   * 2-h Plasma Glucose (2h-PG) ≥ 200 mg\u002FdL (11.1 mmol\u002FL) during the oral glucose tolerance test (OGTT);\n   * A1C ≥ 6.5% (48 mmol\u002Fml);\n4. Willing to attend all study visits of both the run-in and randomized phases of the trial.\n\nExclusion Criteria:\n\n1. Definitive indication for ASA, including any evidence of clinical atherosclerotic disease, previous or current;\n2. Known hypersensitivity to ASA;\n3. Patient requiring dialysis;\n4. Severe hepatic insufficiency or ALT \\> 3 x ULN;\n5. High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract;\n6. Bleeding diathesis;\n7. Platelet count or hemoglobin levels outside of the normal reference range;\n8. Planned major surgical procedure or dental procedure during the course of the study;\n9. Chronic inflammatory disease requiring regular anti-inflammatory treatment;\n10. Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids;\n11. Active cancer;\n12. History of hematological malignancy or myelodysplasia;\n13. Pregnant or lactating women;",{"count":151,"type":20},30,[153],"PHASE1","This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a larger scale trial, and to determine the regimen associated with the lowest proportion of non-responders after randomization. Platelet function will be assessed at baseline and at day 7 of each arms of the study.",[156,157,120,158,30],"Platelet Aggregation","Type 2 Diabetes","Diabetes Mellitus, Type 2",[160,161,162,163],"diabetes","aspirin","Acetylsalicylic acid","Pharmacodynamics","2025-12-02",{"date":166,"type":41},"2025-12-03",{"date":168,"type":41},"2023-06-13",{"date":170,"type":20},"2027-07-01",{"name":172,"class":48},"Montreal Heart Institute",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":198,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":142},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":183,"type":20},50,[23],"The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[187,188,189,156,190,191,192,30,193,194,195,196,197],"ACS - Acute Coronary Syndrome","Ticagrelor","Microbiota","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[199,200,201,202,203,204,205,206,207,208],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","NOT_YET_RECRUITING","2025-09-25",{"date":212,"type":41},"2025-10-02",{"date":214,"type":20},"2026-01-01",{"date":82,"type":20},{"name":217,"class":48},"Collegium Medicum w Bydgoszczy",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100495553","algorithm-based-tailoring-of-dual-antiplatelet-therapy-to-improve-outcomes-following-percutaneous-coronary-interventions-100495553","NCT05732701","Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions","TAILOR-DAPT","Inclusion Criteria:\n\n1. PCI with drug eluting stent (DES) implantation\n2. Age ≥18 years\n3. Ability to sign informed consent before any study-specific procedure\n\nExclusion Criteria:\n\n1. Planned staged PCI (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop an indication for percutaneous valve intervention can undergo treatment 30 days after full coronary revascularization)\n2. Indication for oral anticoagulation\n3. Peri-procedural complication which affects DAPT regimen based on the operator's opinion (e.g. untreated flow-limiting angiographic complication, intraprocedural stent thrombosis, persistent vessel occlusion\u002Fno-reflow at the end of the procedure, major side-branch occlusion, puncture-site related or other relevant bleeding)\n4. Treatment for stent thrombosis at qualifying PCI or within 1 year prior to qualifying PCI\n5. Active bleeding requiring medical attention at qualifying PCI\n6. The presence of hemodynamic instability (persistent systolic blood pressure below 90mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and\u002For use of percutaneous left ventricular assist devices)\n7. Life expectancy less than 1 year\n8. Women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile)\n9. Planned surgery within the next 3 months\n10. Contraindication or known allergy against aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel)\n11. Participation in a drug trial",{"count":226,"type":20},2788,[60],"The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.",[230,30,105],"Percutaneous Coronary Intervention","2025-09-15",{"date":233,"type":41},"2025-09-16",{"date":235,"type":41},"2023-06-27",{"date":237,"type":20},"2028-12",{"name":239,"class":48},"Insel Gruppe AG, University Hospital Bern",3]